• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 57Outcomes of ADEPT at 12 weeks for patients in the placebo group, for patients with at least 3% body skin area affected by psoriasis at baseline (n = 69)51

PsARC (x)PASI 75 (y)nf(x,y)
00490.72
0120.03
10170.24
1110.01

From: Appendix 10, Estimation of probability of achieving both Psoriatic Arthritis Response Criteria and Psoriasis Area and Severity Index 75 response

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.